An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

This study is testing a combination of two maintenance therapy drugs — mirvetuximab soravtansine (a targeted antibody-drug) and olaparib (a PARP inhibitor) — for women with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer after completing platinum chemotherapy. **You may be eligible if...** - You are a woman 18 years old or older - You have been diagnosed with high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer - Your cancer responded to (or stabilized on) your most recent platinum-based chemotherapy - Your cancer is platinum-sensitive (progressed more than 6 months after your last platinum treatment) - Your general health is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have platinum-resistant cancer (progressed within 6 months of platinum therapy) - You have severe bone marrow problems or low blood counts - You have serious heart or lung conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.